CNR2 and early-onset autosomal dominant Alzheimer disease: Other CB2 agonists have been or are currently being studied in preclinical and clinical trials, including GW-842,166X for pain [16,45,46] and MDA7/NTRX-07 for pain [49,50,68] and Alzheimer’s disease [51,52], but to date, no CB2 agonist drugs are approved for clinical use.